Premium
Pharmacogenomic screening for anthracycline‐induced cardiotoxicity in childhood cancer
Author(s) -
Aminkeng Folefac,
Ross Colin J. D.,
Rassekh Shahrad R.,
Rieder Michael J.,
Bhavsar Amit P.,
Sanatani Shubhayan,
Bernstein Daniel,
Hayden Michael R.,
Amstutz Ursula,
Carleton Bruce C.
Publication year - 2017
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.13218
Subject(s) - anthracycline , cardiotoxicity , pharmacogenomics , medicine , odds ratio , confidence interval , oncology , heart failure , pharmacology , bioinformatics , cardiology , cancer , biology , chemotherapy , breast cancer
Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada, BC Children’s Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada, Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada, Department of Pediatrics, University of Western Ontario, London, Ontario, Canada, Department of Pediatrics, Division of Cardiology, Stanford University, Stanford, California, USA, Teva Pharmaceutical Industries, Petach Tikva, Israel, University Institute of Clinical Chemistry, Inselspital Bern University Hospital and University of Bern, Switzerland, and Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada